Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Investing Activities (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Cash from Investing Activities data on record, last reported at -$504000.0 in Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 102.48% year-over-year to -$504000.0; the TTM value through Sep 2025 reached -$16.6 million, down 186.33%, while the annual FY2024 figure was $4.2 million, 125.26% up from the prior year.
  • Cash from Investing Activities reached -$504000.0 in Q3 2025 per PLX's latest filing, down from -$438000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $37.4 million in Q4 2021 and bottomed at -$30.7 million in Q1 2021.
  • Average Cash from Investing Activities over 5 years is $7473.7, with a median of -$222000.0 recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: soared 2913.43% in 2021, then plummeted 4379.53% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $37.4 million in 2021, then plummeted by 86.77% to $5.0 million in 2022, then plummeted by 106.9% to -$342000.0 in 2023, then tumbled by 4379.53% to -$15.3 million in 2024, then skyrocketed by 96.71% to -$504000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$504000.0 in Q3 2025, -$438000.0 in Q2 2025, and -$312000.0 in Q1 2025.